Clinical and Anamnestic Characteristics, Cardiovascular Pharmacotherapy and Long-term Outcomes in Multimorbid Patients after COVID-19
| Autor: | A. A. Smirnov, M. M. Loukianov, S. Yu. Martsevich, A. A. Pulin, N. P. Kutishenko, E. Yu. Andreenko, V. P. Voronina, V. A. Dindikova, N. A. Dmitrieva, M. M. Kudryavtseva, O. V. Lerman, A. N. Makoveeva, E. Yu. Okshina, A. A. Maltseva, E. N. Belova, V. G. Klyashtorniy, E. V. Kudryashov, O. E. Karpov, O. M. Drapkina |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Рациональная фармакотерапия в кардиологии, Vol 18, Iss 5, Pp 502-509 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1819-6446 2225-3653 |
| DOI: | 10.20996/1819-6446-2022-09-06 |
| Popis: | Aim. To study the clinical and anamnestic characteristics, pharmacotherapy of cardiovascular diseases (CVD) and long-term outcomes in post-COVID-19 patients with cardiovascular multimorbidity (CVMM), enrolled in the prospective hospital registry.Material and methods. In patients with confirmed COVID-19 included in the TARGET-VIP registry, the CVMM criterion was the presence of two or more CVDs: arterial hypertension (AH), coronary heart disease (CHD), chronic heart failure (CHF), atrial fibrillation (AF). There were 163 patients in the CVMM group and 382 – in the group without CVD. The information was obtained initially from hospital history sheet, and afterwards – from a telephone survey of patients after 30-60 days, 6 and 12 months, from electronic databases. The follow-up period was 13.0±1.5 months.Results. The age of post-COVID patients with CVMM was 73.7±9.6 years, without CVD – 49.4±12.4 years (p0.05). There were higher rate of all-cause mortality among patients with CMMM (12.9% vs 2.9%, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|